Charlotte Höybye
Charlotte Höybye
Department of Endocrinology and Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Beverly M K Biller
Beverly M K Biller
Neuroendocrine Unit, Massachusetts General Hospital, Massachusetts General Hospital, Boston, Massachusetts, USA
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Jean-Marc Ferran
Jean-Marc Ferran
Qualiance ApS, Copenhagen, Denmark
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Murray B Gordon
Murray B Gordon
Allegheny Neuroendocrinology Center, Division of Endocrinology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Nicky Kelepouris
Nicky Kelepouris
US Medical Affairs-Rare Endocrine Disorders, Novo Nordisk, Inc, Plainsboro, New Jersey, USA
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Navid Nedjatian
Navid Nedjatian
Global Medical Affairs – Rare Endocrine Disorders, Novo Nordisk Health Care AG, Zurich, Switzerland
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Anne H Olsen
Anne H Olsen
Epidemiology, Novo Nordisk A/S, Soborg, Denmark
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Matthias M Weber
Matthias M Weber
Unit of Endocrinology, 1, Medical Department, University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg-Universität, Mainz, Germany
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
for AGHD (GH treated) who were enrolled in two non-interventional, multicentre studies: the NordiNet ® International Outcome Study (IOS) and the American Norditropin ® Studies: Web-Enabled Research (ANSWER) Program ( 16 , 17 ). The CV risks of
Alicia Romano
Alicia Romano
Department of Pediatrics, New York Medical College, Valhalla, New York, USA
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Juan Pablo Kaski
Juan Pablo Kaski
Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital & UCL Institute of Cardiovascular Science, London, UK
Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed
Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed
Jovanna Dahlgren
Jovanna Dahlgren
Department of Paediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed
Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed
Nicky Kelepouris
Nicky Kelepouris
US Medical Affairs, Novo Nordisk Inc., Plainsboro, New Jersey, USA
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Alberto Pietropoli
Alberto Pietropoli
Global Medical Affairs, Novo Nordisk Health Care AG, Zurich, Switzerland
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Tilman R Rohrer
Tilman R Rohrer
Department of Pediatric Endocrinology, University Children’s Hospital, Saarland University Medical Center, Homburg, Germany
Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed
Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed
Michel Polak
Michel Polak
Paediatric Endocrinology, Diabetology and Gynaecology Department, Hôpital Universitaire Necker Enfants-Malades, AP-HP, Université de Paris, Imagine Institute, Paris, France
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
good safety profile ( 6 , 7 ). Norditropin® (Novo Nordisk A/S) is currently the only GH replacement therapy approved internationally for the treatment of short stature in children with NS (in the United States, Canada, European Union, UK, Japan, Israel
